Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States
| Autor: | Omar A. Rey, Raja Atallah, Allan H. Smith, Craig Steinmaus, Dave Kalman, Yan Yuan, Lee E. Moore, Michael N. Bates, Mary L. Biggs, Bruce K. Hoang, Claudia Hopenhayn |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Urinary system Argentina chemistry.chemical_element Gastroenterology Methylation Arsenic Internal medicine Epidemiology medicine Odds Ratio Humans Aged Bladder cancer business.industry Public Health Environmental and Occupational Health Case-control study Cancer Odds ratio Middle Aged medicine.disease Confidence interval United States Surgery chemistry Urinary Bladder Neoplasms Case-Control Studies Female business |
| Zdroj: | Journal of occupational and environmental medicine. 48(5) |
| ISSN: | 1076-2752 |
| Popis: | Objective: We sought to assess whether the metabolism of arsenic impacts a person’s susceptibility to bladder cancer. Methods: Urinary methylation products were measured in subjects from Argentina (114 cases and 114 controls) and the United States (23 cases and 49 controls). Results: In Argentina, the adjusted odds ratio (OR) for subjects with a high proportion of ingested arsenic excreted as monomethylarsonate (%MMA) was 2.17 (95% confidence interval [CI] 1.02–4.63) in smokers and 0.48 (95% CI 0.17–1.33) in nonsmokers. In the United States, the adjusted ORs for high %MMA in subjects with arsenic intakes less than and greater than 100 g/d were 1.20 (95% CI 0.27–5.38) and 2.70 (95% CI 0.39–18.6). Conclusions: Overall, these results are consistent with data from Taiwan suggesting that some individuals who excrete a higher proportion of ingested arsenic as MMA are more susceptible to arsenic-related cancer. (J Occup Environ Med. 2006;48: 478–488) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|